Cargando…

The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment

PURPOSE: To prospectively evaluate the feasibility of solid gold marker placement in oesophageal cancer patients and to quantify inter-fractional and intra-fractional (baseline shift) marker motion during radiation treatment. Radiotherapy target margins and matching strategies were investigated. MAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Melissa, De Roover, Robin, van der Merwe, Schalk, Lambrecht, Maarten, Defraene, Gilles, Haustermans, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677672/
https://www.ncbi.nlm.nih.gov/pubmed/33251342
http://dx.doi.org/10.1016/j.ctro.2020.11.001
_version_ 1783612022316859392
author Thomas, Melissa
De Roover, Robin
van der Merwe, Schalk
Lambrecht, Maarten
Defraene, Gilles
Haustermans, Karin
author_facet Thomas, Melissa
De Roover, Robin
van der Merwe, Schalk
Lambrecht, Maarten
Defraene, Gilles
Haustermans, Karin
author_sort Thomas, Melissa
collection PubMed
description PURPOSE: To prospectively evaluate the feasibility of solid gold marker placement in oesophageal cancer patients and to quantify inter-fractional and intra-fractional (baseline shift) marker motion during radiation treatment. Radiotherapy target margins and matching strategies were investigated. MATERIALS/METHODS: Thirty-four markers were implanted by echo-endoscopy in 10 patients. Patients received a planning 4D CT, daily pre-treatment cone-beam CT (CBCT) and a post-treatment CBCT for at least five fractions. For fractions with both pre- and post-treatment CBCT, marker displacement between planning CT and pre-treatment CBCT (inter-fractional) and between pre-treatment and post-treatment CBCT (intra-fractional; only for fractions without rotational treatment couch correction) were calculated in left–right (LR), cranio-caudal (CC) and anterior-posterior (AP) direction after bony-anatomy and soft-tissue matching. Systematic/random setup errors were estimated; treatment margins were calculated. RESULTS: No serious adverse events occurred. Twenty-three (67.6%) markers were visible during radiotherapy (n = 3 middle oesophagus, n = 16 distal oesophagus, n = 4 proximal stomach). Margins for inter-fractional displacement after bony-anatomy match depended on the localisation of the primary tumour and were 11.2 mm (LR), 16.4 mm (CC) and 8.2 mm (AP) for distal markers. Soft-tissue matching reduced the CC margin for these markers (16.4 mm to 10.5 mm). The mean intra-fractional shift of 12 distal markers was 0.4 mm (LR), 2.3 mm (CC) and 0.7 mm (AP). Inclusion of this shift resulted in treatment margins for distal markers of 12.8 mm (LR), 17.3 mm (CC) and 10.4 mm (AP) after bony-anatomy matching and 12.4 mm (LR), 11.4 mm (CC) and 9.7 mm (AP) after soft-tissue matching. CONCLUSION: This study demonstrated that the implantation of gold markers was safe, albeit less stable compared to other marker types. Inter-fractional motion was largest cranio-caudally for markers in the distal oesophagus, which was reduced after soft-tissue compared to bony-anatomy matching. The impact of intra-fractional baseline shifts on margin calculation was rather small.
format Online
Article
Text
id pubmed-7677672
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-76776722020-11-27 The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment Thomas, Melissa De Roover, Robin van der Merwe, Schalk Lambrecht, Maarten Defraene, Gilles Haustermans, Karin Clin Transl Radiat Oncol Original Research Article PURPOSE: To prospectively evaluate the feasibility of solid gold marker placement in oesophageal cancer patients and to quantify inter-fractional and intra-fractional (baseline shift) marker motion during radiation treatment. Radiotherapy target margins and matching strategies were investigated. MATERIALS/METHODS: Thirty-four markers were implanted by echo-endoscopy in 10 patients. Patients received a planning 4D CT, daily pre-treatment cone-beam CT (CBCT) and a post-treatment CBCT for at least five fractions. For fractions with both pre- and post-treatment CBCT, marker displacement between planning CT and pre-treatment CBCT (inter-fractional) and between pre-treatment and post-treatment CBCT (intra-fractional; only for fractions without rotational treatment couch correction) were calculated in left–right (LR), cranio-caudal (CC) and anterior-posterior (AP) direction after bony-anatomy and soft-tissue matching. Systematic/random setup errors were estimated; treatment margins were calculated. RESULTS: No serious adverse events occurred. Twenty-three (67.6%) markers were visible during radiotherapy (n = 3 middle oesophagus, n = 16 distal oesophagus, n = 4 proximal stomach). Margins for inter-fractional displacement after bony-anatomy match depended on the localisation of the primary tumour and were 11.2 mm (LR), 16.4 mm (CC) and 8.2 mm (AP) for distal markers. Soft-tissue matching reduced the CC margin for these markers (16.4 mm to 10.5 mm). The mean intra-fractional shift of 12 distal markers was 0.4 mm (LR), 2.3 mm (CC) and 0.7 mm (AP). Inclusion of this shift resulted in treatment margins for distal markers of 12.8 mm (LR), 17.3 mm (CC) and 10.4 mm (AP) after bony-anatomy matching and 12.4 mm (LR), 11.4 mm (CC) and 9.7 mm (AP) after soft-tissue matching. CONCLUSION: This study demonstrated that the implantation of gold markers was safe, albeit less stable compared to other marker types. Inter-fractional motion was largest cranio-caudally for markers in the distal oesophagus, which was reduced after soft-tissue compared to bony-anatomy matching. The impact of intra-fractional baseline shifts on margin calculation was rather small. Elsevier 2020-11-05 /pmc/articles/PMC7677672/ /pubmed/33251342 http://dx.doi.org/10.1016/j.ctro.2020.11.001 Text en © 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Thomas, Melissa
De Roover, Robin
van der Merwe, Schalk
Lambrecht, Maarten
Defraene, Gilles
Haustermans, Karin
The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
title The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
title_full The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
title_fullStr The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
title_full_unstemmed The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
title_short The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
title_sort use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677672/
https://www.ncbi.nlm.nih.gov/pubmed/33251342
http://dx.doi.org/10.1016/j.ctro.2020.11.001
work_keys_str_mv AT thomasmelissa theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT derooverrobin theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT vandermerweschalk theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT lambrechtmaarten theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT defraenegilles theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT haustermanskarin theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT thomasmelissa useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT derooverrobin useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT vandermerweschalk useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT lambrechtmaarten useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT defraenegilles useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment
AT haustermanskarin useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment